Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Are peptides legal in Georgia?

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Yes, but Georgia is one of the stricter telehealth states. A Georgia resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from a Georgia-licensed provider, but Georgia Composite Medical Board rule 360-3-.07 generally requires the patient to have been examined in person by a Georgia licensee (or the prescriber to act at that licensee's request) or examined with technology equal or superior to an in-person exam before an initial dangerous drug prescription by telemedicine, and the Board ended its pandemic-era flexibility in 2024. Compounded peptides are available when eligible under federal 503A rules and dispensed by a Georgia pharmacy or a pharmacy holding a Georgia nonresident pharmacy permit (O.C.G.A. 26-4-114.1); nonresident pharmacies that compound must also submit an inspection report.

Regulatory: Telehealth allowedRegulatory: Async not allowedRegulatory: Compounded GLP-1 limitedVerified: Verified Oct 28, 2026
Compounding rules
Follows the federal 503A framework
Telehealth prescribing
Allowed, asynchronous not allowed
Compounded GLP-1
Limited

Can a Georgia resident get peptides by telehealth?

Georgia Composite Medical Board rule 360-3-.07 (Practice through electronic or other such means) allows treatment by electronic means by a Georgia-licensed physician, physician assistant, or advanced practice registered nurse who has personally seen and examined the patient, is acting at the request of a Georgia-licensed clinician who has, or is able to examine the patient using technology or peripherals that are equal or superior to an examination done personally. Board rule 360-3-.02(6) makes it unprofessional conduct to provide treatment by electronic means unless a history and physical examination of the patient has been performed by a Georgia licensee, with exceptions for on-call coverage and consultations. Rule 360-3-.02(5) makes it unprofessional conduct to prescribe controlled substances or dangerous drugs based solely on a consultation via electronic means, but does not prohibit prescribing a dangerous drug under a valid physician-patient relationship in accordance with O.C.G.A. 33-24-56.4, the Georgia Telehealth Act, an insurance statute that does not change the standard of care. Under O.C.G.A. 16-13-71 a dangerous drug is any non-scheduled drug that federal law allows to be dispensed only by prescription. This record reads that to include prescription-only GLP-1 drugs that are not scheduled; the statute does not name any drug. Both statutes were read on Justia's 2025 edition, not the official code. In its January 10, 2024 statement the Board said an in-person visit is not required for every prescription, but that its rules in general require a patient to be examined once in person before an initial prescription for controlled substances and/or dangerous drugs, that licensees should follow the Medical Practice Act and Board rules as of May 1, 2024, and that telemedicine providers must make diligent efforts to have patients examined in person annually. Out-of-state providers need a Georgia license. Rule 360-3-.07 has not changed since September 28, 2020 and rule 360-3-.02 was last amended effective August 27, 2024 (Administrative Code current through September 2, 2026). This record classifies asynchronous prescribing as not allowed because the Board's rules require an actual examination of a new patient, in person or with technology equal or superior to an in-person exam, before a first dangerous drug prescription, and the Board's own statement reads them as generally requiring one in-person exam. A questionnaire or other asynchronous review alone does not meet that. No Board rule names online questionnaires specifically. [2] [3] [7] [8] [9] [10]

How does the Georgia pharmacy board treat compounding?

Compounding regulator for Georgia
BoardGeorgia State Board of Pharmacy
Eligible substancesFollows the federal 503A framework

The Georgia State Board of Pharmacy regulates pharmacies under O.C.G.A. Title 26, Chapter 4 and Board rules in chapter 480 of the Rules and Regulations of the State of Georgia. Georgia has no separate state bulks list; Board rule 480-11-.02(6) lets pharmacists compound from bulk substances that meet an applicable USP-NF monograph, are components of FDA-approved drugs, or are otherwise approved by FDA, and federal 503A limits apply on top of that. Since July 1, 2013, O.C.G.A. 26-4-114.1 requires any person, pharmacy, or facility outside Georgia that ships, mails, or delivers dispensed drugs into Georgia to hold a Georgia nonresident pharmacy permit; under Board rule 480-6-.02 the pharmacist in charge must be licensed in the pharmacy's home state, and a nonresident pharmacy that performs sterile or non-sterile compounding must submit an inspection report with its application. Compounding standards are in Board rule chapter 480-11 (Pharmaceutical Compounding): rule 480-11-.02(8) makes all sterile compounded preparations subject to USP chapter 797 and non-sterile preparations subject to USP chapter 795, rule 480-11-.02(12)(b) bars compounding essentially copies of commercially available products except for a prescriber-ordered change for an individual patient, unavailability, or a drug-shortage listing, rule 480-11-.04(3) sets the facility and equipment requirements for sterile parenteral compounding, and rule 480-11-.09 requires a quality assurance program for sterile preparations. [1] [5] [6] [11] [13]

Can you get compounded GLP-1s in Georgia?

Regulatory: Compounded GLP-1 limited

The practical Georgia barrier is the prescription itself. Rule 360-3-.07 lets a Georgia-licensed provider treat by telemedicine only if the provider has personally examined the patient, acts at the request of a Georgia licensee who has, or can examine the patient using technology equal or superior to an in-person exam. The Board said on January 10, 2024 that its rules in general require one in-person exam before an initial prescription for a dangerous drug. [3] [4] [8] [16]

Prices by channel: semaglutide cost, tirzepatide cost.

Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.

What is the legal access path in Georgia?

Access options

We may earn a commission from these links.

Prices are the partner's own and are not verified by PeptideAgent. You answer health questions after checkout, and the partner's clinician decides whether to prescribe.

Unsponsored access paths are checked against public regulatory records. Sponsored offers are the partner's and are labeled. Products labeled research use only are never listed.

Find a provider in Georgia

What you'll actually find in Georgia, and how to check

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [20] [21] [22]

No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [23]

What Georgia has done

PeptideAgent has not found a board or legislative action on peptides in Georgia.

Other states have acted:

  • On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [25] Mississippi law
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [26] [27] Louisiana law

Checking the prescriber

Telehealth prescribing of non-controlled peptides is permitted in Georgia. Expect a live video or phone visit; prescribing without one is not permitted. [2] [3] [7] [8] [9] [10] The telehealth rule in full.

Checking the pharmacy

Look the pharmacy up yourself before you pay, including an out-of-state mail-order pharmacy. The pharmacy regulator is the Georgia State Board of Pharmacy; its license search: FDA BeSafeRx: state board of pharmacy license lookups. [24]

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [23]

They do not change a peptide's legal status either. That depends on the peptide: for a withdrawn nomination such as BPC-157 or TB-500, a 503A pharmacy has no federal basis to compound it from bulk, with or without a prescription, while a few Category 1 substances, such as NAD+ and glutathione, are compounded under FDA's interim policy, with conditions. Each peptide page gives its status. [14] [28] [29]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [24] [30] [31]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [22] [31] [32]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [23] [33] [34] [35] [36] [37]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [23]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [24]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [22]
  • Pharmacy: Is this made for me on a prescription written in my name? [32]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [22] [31]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [22]

What is offered for a specific peptide, and what FDA found, is on each peptide page.

Is it legal to buy research peptides in Georgia?

Only Georgia-licensed pharmacies and permitted nonresident pharmacies may dispense prescription drugs to Georgia patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law regardless of labeling and are not dispensed by a pharmacist. Georgia law also bars the sale directly: O.C.G.A. 26-3-10 provides that no person shall sell, deliver, offer for sale, hold for sale, or give away any new drug unless an application for it has become effective under section 505 of the federal act (or, for a drug not subject to the federal act, a state application has been filed with the State Board of Pharmacy), with an exemption only for drugs intended solely for investigational use by qualified experts and plainly labeled "For investigational use only." [5] [12] [17]

Peptide-specific notes for Georgia

Peptide-specific notes for Georgia
PeptideNote
SemaglutideAvailable branded by prescription, but a first telemedicine prescription in Georgia generally requires a prior in-person exam or an exam with technology equal or superior to one under rule 360-3-.07. Compounded semaglutide is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025. [3] [16]
TirzepatideAvailable branded by prescription under the same Georgia telemedicine exam rule. Compounded tirzepatide is limited to documented patient-specific needs since the 503A grace period ended February 18, 2025, and must come from a Georgia or permitted nonresident pharmacy. [3] [5] [16]

Compare: Wegovy vs Zepbound.

Frequently asked questions

Do I need an in-person visit to get a GLP-1 prescription by telehealth in Georgia?

Usually, or an exam using technology that is equal or superior to one. Georgia Composite Medical Board rule 360-3-.07 allows telemedicine prescribing when the provider has examined you in person, is acting at the request of a Georgia clinician who has, or can examine you with technology equal or superior to an in-person exam, and the Board has said its rules in general require one in-person exam before an initial dangerous drug prescription. No rule names online questionnaires, but a questionnaire alone does not meet that exam requirement. [3] [7] [8]

Did Georgia's pandemic telehealth flexibility end?

Yes. The Georgia Composite Medical Board announced in December 2023 that it was rescinding its COVID-era tele-prescribing position, extended the change to May 1, 2024, and now requires licensees to follow the Medical Practice Act and Board rules for prescribing. [4] [8]

What does an out-of-state pharmacy need to ship compounded peptides to Georgia?

A Georgia nonresident pharmacy permit under O.C.G.A. 26-4-114.1. Under Board rule 480-6-.02, a nonresident pharmacy that compounds must also submit an inspection report when it applies. Verify the permit on the Georgia Board of Pharmacy license lookup. [5] [6]

Can a Georgia pharmacy compound BPC-157?

Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). State law still applies: Georgia has no separate state bulks list; Board rule 480-11-.02(6) lets pharmacists compound from bulk substances that meet an applicable USP-NF monograph, are components of FDA-approved drugs, or are otherwise approved by FDA, and federal 503A limits apply on top of that. [11] [14] [15] [18] [19]

From the blog

Sources

Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, federal FDA guidance, and the FDA warning letters and studies behind what is offered.

  1. [1]Georgia State Board of Pharmacy
  2. [2]Georgia Composite Medical Board
  3. [3]Georgia Composite Medical Board rule 360-3-.07, Practice through electronic or other such means (chapter 360-3)
  4. [4]Georgia Composite Medical Board: Board updates position on telehealth prescribing (December 7, 2023)
  5. [5]O.C.G.A. 26-4-114.1, Nonresident pharmacy permits
  6. [6]Georgia Board of Pharmacy rule 480-6-.02, Nonresident pharmacy permit
  7. [7]Georgia Composite Medical Board rule 360-3-.02, Unprofessional conduct defined (paragraph (6), treatment by electronic means; amended effective August 27, 2024), accessed 2026-09-22
  8. [8]Georgia Composite Medical Board: Board extends tele-prescribing flexibility until May 1 (January 10, 2024), accessed 2026-09-22
  9. [9]O.C.G.A. 16-13-71, Dangerous drug (definition), accessed 2026-09-22
  10. [10]O.C.G.A. 33-24-56.4, Georgia Telehealth Act (definitions; referenced in Board rule 360-3-.02(5); Justia 2025 edition), accessed 2026-09-30

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). Are peptides legal in Georgia?. https://peptideagent.ai/legal/georgia
HTML link
<a href="https://peptideagent.ai/legal/georgia">Are peptides legal in Georgia?</a>, PeptideAgent, updated October 28, 2026.